Abbott announced positive results from studies on its Volt Pulsed Field Ablation system for treating atrial fibrillation, reinforcing its long-term safety and effectiveness. The Volt PFA System demonstrated a high success rate, with nearly 68% of patients remaining free from additional AFib episodes and a low repeat ablation rate. Additionally, Abbott presented positive results for its TactiFlex Duo Ablation Catheter, designed for tailored AFib therapy, further strengthening its commitment to advancing cardiac care.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Abbott reports positive results from study on its atrial fibrillation therapies
Abbott announced positive results from studies on its Volt Pulsed Field Ablation system for treating atrial fibrillation, reinforcing its long-term safety and effectiveness. The Volt PFA System demonstrated a high success rate, with nearly 68% of patients remaining free from additional AFib episodes and a low repeat ablation rate. Additionally, Abbott presented positive results for its TactiFlex Duo Ablation Catheter, designed for tailored AFib therapy, further strengthening its commitment to advancing cardiac care.